ArticleTrends in pharmacological sciences2021
Therapeutic Potential of Targeting Plasminogen Activator Inhibitor-1 in COVID-19.
Article in Trends in pharmacological sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- Inflammation-driven mitochondrial dysfunction and ROS accumulation orchestrate pulmonary fibrotic remodeling in sepsis.Redox biology · 2026Article
- Xylooligosaccharide in combination with Lactobacillus rhamnosus ameliorates disturbed circadian rhythm and associated neurological internal desynchronization by maintaining homeostasis of neuroactive molecules and gut microbiome.Archives of microbiology · 2026Article
- Targeting Plasminogen Activator Inhibitor-1 with a Novel Small Molecule Inhibitor Attenuates Lung Fibrosis.Research square · 2025Article
- Integrated histopathology, spatial and single cell transcriptomics resolve cellular drivers of early and late alveolar damage in COVID-19.Nature communications · 2025Article
- Identifying Mechanism of Resveratrol for the Treatment of COVID-19 and Idiopathic Pulmonary FibrosisCurrent medicinal chemistry · 2025Article
- Integrated multi-omics analyses identify anti-viral host factors and pathways controlling SARS-CoV-2 infection.Nature communications · 2024Article
- Tracking inflammation resolution signatures in lungs after SARS-CoV-2 omicron BA.1 infection of K18-hACE2 mice.PloS one · 2024Article
- Role of early growth response 1 in inflammation-associated lung diseases.American journal of physiology. Lung cellular and molecular physiology · 2023Review
- Plasminogen activator inhibitor 1 is not a major causative factor for exacerbation in a mouse model of SARS-CoV-2 infection.Scientific reports · 2023Article
- Complement as a vital nexus of the pathobiological connectome for acute respiratory distress syndrome: An emerging therapeutic target.Frontiers in immunology · 2023Review
- Serum Proteomic Analysis for New Types of Long-Term Persistent COVID-19 Patients in Wuhan.Microbiology spectrum · 2022Article
- The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication.Signal transduction and targeted therapy · 2022Review
- Methotrexate inhibition of SARS-CoV-2 entry, infection and inflammation revealed by bioinformatics approach and a hamster model.Frontiers in immunology · 2022Article
- SERPINE1 Gene Is a Reliable Molecular Marker for the Early Diagnosis of Aortic Dissection.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- A Vicious Cycle: In Severe and Critically Ill COVID-19 Patients.Frontiers in immunology · 2022Review
- Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Age and genotype dependent erythropoietin protection in COVID-19.World journal of stem cells · 2021Review
- The Impact of Age and BMI on the VWF/ADAMTS13 Axis and Simultaneous Thrombin and Plasmin Generation in Hospitalized COVID-19 Patients.Frontiers in medicine · 2021Article
- PTSD as an Endothelial Disease: Insights From COVID-19.Frontiers in cellular neuroscience · 2021Review
Corrections and comments
- Comment on
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Latest research shows that SERPINE1 overexpression has an important role in Coronavirus 2019 (COVID-19)-associated coagulopathy leading to acute respiratory distress syndrome (ARDS). However, ways to target this protein remain elusive. In this forum, we discuss recent evidence linking SERPINE1 with COVID-19-related ARDS and summarize the available data on inhibitors of this target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.